Gilead Sciences GILD
NASDAQ GILD
$146.12 +2.68 (+1.87%)
At close: Aug 21, 2026 · 4:00 PM EDT

Gilead Sciences (GILD) Income from Continuing Operations (2009 - 2026)

Gilead Sciences' (GILD) quarterly Income from Continuing Operations came in at 2021000000.0 in Q1 2026, up 53.69% YoY from 1315000000.0 in Q1 2025, and down 20.06% on a QoQ basis from 2528000000.0 in Q4 2025.

Gilead Sciences (GILD) Income from Continuing Operations (2009 - 2026) Analysis & Trends

Gilead Sciences (GILD) has 18 years of Income from Continuing Operations data on file, last reported at 2021000000.0 in Q1 2026.

  • Quarterly Income from Continuing Operations rose 53.69% year-over-year to 2021000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9562000000.0 (up 60.3% YoY) and the FY2025 annual result came in at 8510000000.0, up 1676.62% from the prior year.
  • Income from Continuing Operations eased to 2021000000.0 in Q1 2026, from 2528000000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 3052000000.0 in Q3 2025 to a low of 4171000000.0 in Q1 2024.
  • A 5-year average of 1266647058.82 and a median of 1615000000.0 in 2024 frame the typical range for Income from Continuing Operations.
  • Annual changes were most pronounced in 2023 — Income from Continuing Operations jumped 8100.0% — and 2024, when it slumped 523.88%.
  • Tracing GILD's Income from Continuing Operations over 5 years: stood at 1633000000.0 in 2022, then dropped by 13.29% to 1416000000.0 in 2023, then advanced by 25.85% to 1782000000.0 in 2024, then soared by 41.86% to 2528000000.0 in 2025, then dropped by 20.06% to 2021000000.0 in 2026.
  • The last three Income from Continuing Operations figures came in at 2021000000.0 (Q1 2026), 2528000000.0 (Q4 2025), and 3052000000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn 5.53 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn 3.62 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn -1.34 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn 3.26 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn 2.51 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn 2.38 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn -10.50 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn -246.00 Mn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn 207.96 Mn
10 Sanofi 55.07 Bn 47.69 Bn 10.79 Bn 17.71 Bn

Historic Data

Download Data
DateValue
Jun 30, 2026 -10.50 Bn
Mar 31, 2026 2.02 Bn
Dec 31, 2025 2.53 Bn
Sep 30, 2025 3.05 Bn
Jun 30, 2025 1.96 Bn
Mar 31, 2025 1.32 Bn
Dec 31, 2024 1.78 Bn
Sep 30, 2024 1.25 Bn
Jun 30, 2024 1.62 Bn
Mar 31, 2024 -4.17 Bn
Dec 31, 2023 1.42 Bn
Sep 30, 2023 2.17 Bn
Jun 30, 2023 1.04 Bn
Mar 31, 2023 984.00 Mn
Dec 31, 2022 1.63 Bn
Sep 30, 2022 1.79 Bn
Jun 30, 2022 1.14 Bn
Mar 31, 2022 12.00 Mn
Dec 31, 2021 376.00 Mn
Sep 30, 2021 2.59 Bn